|
Tumor | Location | Major findings | References |
|
| Serum and urine | sE-cad exerted prooncogenic effects | Brouxhon et al., 2013 [36] |
| Serum | sE-cad may be a candidate marker for the prediction of response to PST | Hofmann et al., 2013 [35] |
BC | Serum | Preoperative sE-cad levels were higher in invasive tumor and changed after surgery | Perez-Rivas et al., 2012 [31] |
| Cell medium | sE-cad release appeared to be regulated by NGF during the BC cell induction of an invasive phenotype | Dollé et al., 2005 [34] |
| Serum | sE-cad levels positively correlated with the pre- and posttherapeutic tumor size as well as the disease-free interval | Hofmann et al., 2005 [33] |
|
|
Serum | sE-cad was a good marker predicting the disease recurrence in the first 3–6 months after surgery | Chan et al., 2005 [38] |
| Serum | sE-cad was an independent factor predicting long-term survival, and it was proposed as a valuable pretherapeutic prognostic factor in GC | Chan et al., 2003 [39] |
GC | Serum | sE-cad levels increased in intestinal-type GC, especially in advanced stages, and sE-cad was proposed as prognostic marker | Juhasz et al., 2003 [40] |
| Serum | sE-cad resulted in a potential valid prognostic marker for GC | Chan et al., 2001 [41] |
| Serum | Tumor tissues showed higher sE-cad levels, which were proposed as excellent tumor markers with high sensitivity | Gofuku et al., 1998 [42] |
|
|
Secretome* | More than 170 proteins were identified, including the E-cad | Imperlini et al., 2013 [43] |
| Serum | An elevated sE-cad level was a risk factor for predicting poor prognosis and hepatic metastasis | Okugawa et al., 2012 [44] |
CRC | Serum, secretome, and tissue | In patients with late-stage CRC, serum sE-cad levels directly increased and they were proposed as diagnostic biomarker |
Weiß et al., 2011 [45] |
| Serum | sE-cad was proposed as potential marker but not for a routine clinical use because of the lack of specificity | Wilmanns et al., 2004 [46] |
| Serum | Even if elevated in some patients, sE-cad concentrations were not significantly elevated compared with those of controls | Velikova et al., 1998 [47] |
|
BlC |
Urine | Urinary sE-cad values were not greater than urinary total protein content | Protheroe et al., 1999 [48] |
Serum | sE-cad concentrations were higher in BlC patients, and they were correlated with known prognostic factors | Griffiths et al., 1996 [49] |
BlC and urinary disorders | Urine | This is the first evidence of sE-cad forms in urine, which were proposed for diagnosis and prognosis of urinary disorders | Banks et al., 1995 [50] |
TCC of the urinary BlC | Urine | sE-cad levels were higher in TCC patients and they strongly correlated with tumor grade | Shi et al., 2008 [51] |
Cell medium and urine | Higher sE-cad levels were associated with positive cytology results and muscle invasive tumor stage | Shariat et al., 2005 [52] |
Serum | Higher levels of sE-cad correlated with increasing tumor grade but not with clinicopathological stage | Durkan et al., 1999 [53] |
MIBlC | Plasma | Preoperative plasma levels of sE-cad were higher in patients with metastases to regional and distant lymph nodes | Matsumoto et al., 2003 [54] |
|
HCC |
Serum | sE-cad levels were elevated in HCC patients and their levels were proposed as potential HCC prognostic marker | Soyama et al., 2008 [55] |
|
HD | Serum | In HD patients, at diagnosis, sE-cad levels decreased, even if they were not statistically significant, in comparison to healthy controls | Syrigos et al., 2004a [56] |
|
LC | Serum | Circulating sE-cad levels were higher in NSCL patients, but without any statistical evidence as prognostic factor of cell survival | Syrigos et al., 2004b [57] |
|
MM |
Serum | Circulating sE-cad levels were higher in MM patients and were proposed as prognostic factor of cell survival | Gogali et al., 2010 [58] |
Cell medium | sE-cad influenced tumor invasion and it was proposed to play multiple functional roles than cell adhesion | Charalabopoulos et al., 2006 [59] |
|
PCa |
Serum | sE-cad concentration highly statistically decreased after surgery in 82% patients | Iacopino et al., 2012 [60] |
Serum and tissue | This was the first report of sE-cad detection in neoplastic PCa, and sE-cad was proposed as biomarker for PCa disease progression | Kuefer et al., 2003 [61] |
|
SCC |
Serum | sEcad induced SCC proliferation and migration and was proposed as a therapeutic target in coetaneous SCCs | Brouxhon et al., 2014 [37] |
|